<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>NSAIDs: Adverse effects on the distal small bowel and colon</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">NSAIDs: Adverse effects on the distal small bowel and colon</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">NSAIDs: Adverse effects on the distal small bowel and colon</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Louis-Michel Wong Kee Song, MD, FRCP(C)</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Norman E Marcon, MD, FRCP(C)</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Mark Feldman, MD, MACP, AGAF, FACG</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Shilpa Grover, MD, MPH, AGAF</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jan 29, 2024.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>The distal small bowel and colon are susceptible to the deleterious effects of nonsteroidal antiinflammatory drugs (NSAIDs) [<a href="#rid1">1-5</a>]. The ileocecal region is a potential site for a variety of NSAID-induced injuries including erosions, ulcers, strictures, perforation, and the formation of diaphragms, which can lead to bowel obstruction [<a href="#rid6">6-9</a>]. NSAIDs can also lead to colitis resembling inflammatory bowel disease (IBD), exacerbate preexisting IBD, or complicate diverticular disease (ie, perforation or bleeding) [<a href="#rid10">10,11</a>]. Older adults and those on long-term NSAID therapy appear to be at highest risk [<a href="#rid11">11</a>]. There may also be an association between NSAID use and collagenous colitis. (See  <a class="medical medical_review" href="/z/d/html/4071.html" rel="external">"Microscopic (lymphocytic and collagenous) colitis: Clinical manifestations, diagnosis, and management"</a>.)</p><p class="headingAnchor" id="H2"><span class="h1">STUDIES OF NSAID INJURY</span><span class="headingEndMark"> — </span>A number of studies using different methodologies have evaluated the potential deleterious effects of nonsteroidal antiinflammatory drugs (NSAIDs) on the small bowel and colon. Considered together, they suggest that NSAID-related intestinal injury is common. However, the proportion of patients who develop clinically important NSAID-induced enteropathy remains relatively small.</p><p>The following summarizes the range of findings:</p><p class="bulletIndent1"><span class="glyph">●</span>Approximately two-thirds of NSAID users demonstrate intestinal inflammation by indirect methods of 111-Indium-labeled leukocyte scintigraphy and 111-Indium fecal excretion [<a href="#rid12">12</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a case-control study, patients with small or large bowel perforation or bleeding were more than twice as likely to be NSAID users [<a href="#rid13">13</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>An autopsy study evaluated 713 patients, 249 of whom had used NSAIDs in the six months prior to death [<a href="#rid14">14</a>]. Nonspecific small intestinal ulceration (defined as ulcers &gt;3 mm in diameter) was much more common in those who had taken NSAIDs (8.4 versus 0.6 percent in nonusers). Three of the 21 patients with small intestinal ulcers died from perforation of an intestinal ulcer.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A study involving double balloon enteroscopy found that 50 percent of NSAID users had small bowel mucosal breaks compared with only 5 percent in controls [<a href="#rid15">15</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>At least six studies have used video capsule endoscopy to assess small bowel injury associated with NSAIDs, two of which [<a href="#rid1">1,16</a>] had a randomized design [<a href="#rid1">1-4,16,17</a>]. A common finding is the observation that small bowel mucosal abnormalities are relatively common in healthy individuals. In one study, for example, 7 percent of placebo treated patients developed such findings during the course of the study, and an additional 14 percent of healthy subjects who had been screened for the study were excluded because of baseline mucosal abnormalities [<a href="#rid1">1</a>].</p><p></p><p class="headingAnchor" id="H3"><span class="h2">COX-2 inhibitors</span><span class="headingEndMark"> — </span>Studies evaluating the relative safety of COX-2 inhibitors versus nonselective NSAIDs have shown mixed results. Considered together, they suggest that COX-2 inhibitors are not fully protective against clinically important lower gastrointestinal (GI) events and may not be more protective than some nonselective NSAIDs.</p><p class="bulletIndent1"><span class="glyph">●</span>By far the largest study included 34,701 patients with osteoarthritis or rheumatoid arthritis who were older than 50 who were randomly assigned to etoricoxib (60 or 90 mg daily) or <a class="drug drug_general" data-topicid="9348" href="/z/d/drug information/9348.html" rel="external">diclofenac</a> (150 mg daily) for an average of 18 months [<a href="#rid18">18</a>]. Major lower GI clinical events (such as gross or occult rectal bleeding with hemodynamic instability without an upper GI cause) occurred in a similar proportion of patients (0.32 versus 0.38 per 1000 patient-years, respectively). On multivariable analysis, risk factors included a prior lower GI event (hazard ratio [HR] 4.06) or age ≥65 (HR 1.98).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>By contrast, an earlier post-hoc analysis of a large outcome study found a 54 percent reduction in the risk of lower GI events with rofecoxib compared with <a class="drug drug_general" data-topicid="9682" href="/z/d/drug information/9682.html" rel="external">naproxen</a> [<a href="#rid19">19</a>]. A possible explanation for the difference is that naproxen is a more potent inhibitor of platelet function than <a class="drug drug_general" data-topicid="9348" href="/z/d/drug information/9348.html" rel="external">diclofenac</a>, thus increasing the rate of lower GI events in the comparator group.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Other studies have compared COX-2 inhibitors to combination therapy with a proton pump inhibitor plus a nonselective NSAID. One trial included 120 healthy volunteers who were randomly assigned to <a class="drug drug_general" data-topicid="8847" href="/z/d/drug information/8847.html" rel="external">celecoxib</a>, <a class="drug drug_general" data-topicid="9682" href="/z/d/drug information/9682.html" rel="external">naproxen</a> plus <a class="drug drug_general" data-topicid="9718" href="/z/d/drug information/9718.html" rel="external">omeprazole</a>, or placebo [<a href="#rid1">1</a>]. After two weeks, all patients underwent video capsule endoscopy. Significantly more mucosal breaks were observed in the naproxen-omeprazole group compared with the celecoxib group. The proportion of patients with mucosal breaks was correspondingly higher (55 versus 16 and 7 percent in the naproxen-omeprazole, celecoxib, and placebo groups, respectively). Similar conclusions were reached in a second controlled trial that compared lumiracoxib with the combination of naproxen plus omeprazole or placebo [<a href="#rid16">16</a>]. Acute small bowel injury on lumiracoxib was less frequent than with naproxen plus omeprazole and similar to placebo.</p><p></p><p>These data suggest relative protection of the COX-2 inhibitors compared with nonselective NSAIDs plus <a class="drug drug_general" data-topicid="9718" href="/z/d/drug information/9718.html" rel="external">omeprazole</a> against small bowel injury during short-term follow-up. However, the significance of mucosal breaks is unclear. As noted above, there was no difference on major lower GI events in the large randomized study described above. Furthermore, a nonrandomized cohort study found similar rates and types of small bowel injury with long-term use of COX-2 selective agents versus nonselective NSAIDs [<a href="#rid4">4</a>].</p><p class="headingAnchor" id="H4"><span class="h2">Misoprostol</span><span class="headingEndMark"> — </span>Whether <a class="drug drug_general" data-topicid="9657" href="/z/d/drug information/9657.html" rel="external">misoprostol</a> decreases the risk of small bowel lesions from NSAIDs has not been well studied. A small observational study suggested a protective benefit in patients taking enteric-coated low-dose <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a> [<a href="#rid20">20</a>]. Placebo-controlled trials are needed to confirm a potential benefit.</p><p class="headingAnchor" id="H5"><span class="h1">PATHOGENESIS</span><span class="headingEndMark"> — </span>In an attempt to decrease gastroduodenal side effects, the use of enteric-coated, sustained-release, or slow-release nonsteroidal antiinflammatory drugs (NSAIDs) may have shifted the damage to the distal small intestine and colon. A high local concentration of an active NSAID following ingestion or biliary excretion is necessary to increase intestinal permeability, which appears to be a prerequisite for NSAID-induced enteropathy [<a href="#rid12">12,21</a>]. The latter effect, which may be associated with increased bacterial growth, is much more likely to occur with NSAIDs that undergo enterohepatic circulation; secretion of the drug in the bile leads to repeated exposure of the intestinal mucosa to the toxic drug [<a href="#rid22">22</a>]. Studies in an animal model with two related NSAIDs found a progressive increase in epithelial permeability and intestinal ulceration only with the drug that underwent enterohepatic circulation [<a href="#rid22">22</a>].</p><p>NSAIDs may also exert their deleterious effect by localized mucosal injury. In support of this hypothesis are the observations that NSAID capsules have been found at the site of perforating ulcers, that areas of mucosal injury often have sharp demarcations, and that the distal small bowel and proximal colon are typically involved [<a href="#rid7">7,23</a>]. At the mucosal level, postulated mechanisms of injury have included inhibition of protective prostaglandins, alterations in blood flow, and increased small intestinal permeability with subsequent invasion by luminal factors [<a href="#rid6">6</a>]. The mucosal damage may lead to inflammation and ulceration, followed by reparative fibrosis and stricture formation.</p><p>Suppression of gastric acid secretion by proton pump inhibitors (PPIs) is unlikely to provide protection against NSAID-induced damage to the small intestine. In fact, in animal studies PPIs have been demonstrated to exacerbate NSAID-induced intestinal damage due to shifts in enteric microbial populations [<a href="#rid24">24</a>].</p><p>The role of the intestinal microbiota in NSAID-induced enteropathy and use of potential therapeutic agents, such as probiotics and <a class="drug drug_general" data-topicid="10202" href="/z/d/drug information/10202.html" rel="external">rifaximin</a>, are unclear [<a href="#rid25">25,26</a>].</p><p class="headingAnchor" id="H6"><span class="h1">CLINICAL MANIFESTATIONS AND DIAGNOSIS</span><span class="headingEndMark"> — </span>It is likely that most nonsteroidal antiinflammatory drug (NSAID)-induced injuries are subclinical and go unrecognized. When present, symptoms and signs are nonspecific and may include iron deficiency anemia and/or frank bleeding from ulcers; anemia, hypoalbuminemia, or malabsorption from enteropathy; intermittent or complete bowel obstruction from broad-based or diaphragm-like strictures; watery or bloody diarrhea from colitis; and acute abdomen from perforation. The typical patient is one taking an NSAID for a rheumatic condition, such as osteoarthritis or rheumatoid arthritis. The duration of NSAID use to time of diagnosis is widely variable (days to years).</p><p>Virtually all classes of NSAIDs that block both COX-1 and COX-2 have been implicated. Whether the relative safety of the COX-2 selective inhibitors on gastroduodenal injury will be observed in the small and large bowel remains to be established.</p><p class="headingAnchor" id="H7"><span class="h2">Intestinal diaphragms</span><span class="headingEndMark"> — </span>A lesion thought to be pathognomonic of NSAID injury is the diaphragm-like stricture  (<a class="graphic graphic_picture graphicRef59412" href="/z/d/graphic/59412.html" rel="external">picture 1</a>), which is likely a scarring reaction secondary to ulcerative injury. These lesions are thin, concentric, diaphragm-like septa with pinhole-sized lumen  (<a class="graphic graphic_picture graphicRef74226" href="/z/d/graphic/74226.html" rel="external">picture 2</a>). They are usually multiple, found mostly in the mid-intestine, but have also been described in the ileum and colon [<a href="#rid7">7-9,12,27</a>]. They are histologically characterized by submucosal fibrosis with normal overlying epithelium, apart from tip of diaphragm, which may be ulcerated. The mucosa between diaphragms is normal. As a potential cause of subacute obstruction, these strictures are difficult to diagnose since they may appear as exaggerated plica circularis under radiographic imaging  (<a class="graphic graphic_picture graphicRef79919" href="/z/d/graphic/79919.html" rel="external">picture 3</a>). At laparotomy, the surgeon should be alerted to this possibility, since the exterior aspect may look normal and the strictures difficult to palpate. In this regard, intraoperative enteroscopy is helpful.</p><p class="headingAnchor" id="H8"><span class="h2">Endoscopic and histologic findings</span><span class="headingEndMark"> — </span>Findings on capsule endoscopy [<a href="#rid2">2</a>], balloon-assisted enteroscopy [<a href="#rid28">28</a>], and/or colonoscopy may lend support to the diagnosis of NSAID-induced injury, although there is nothing endoscopically specific about NSAID-induced erosions, ulcers  (<a class="graphic graphic_picture graphicRef72227" href="/z/d/graphic/72227.html" rel="external">picture 4</a>), or colitis. Histology is also nonspecific. The differential diagnosis should thus include infectious etiologies (eg, <em>Campylobacter</em>, <em>Yersinia</em>, cytomegalovirus, TB), irritable bowel disease, ischemia, radiation enteritis, vasculitides, and other drugs (eg, <a class="drug drug_general" data-topicid="9795" href="/z/d/drug information/9795.html" rel="external">potassium chloride</a> tablets) [<a href="#rid6">6,7,29</a>]. However, the right diagnosis can usually be made in conjunction with a good history and endoscopic biopsies. Furthermore, the above NSAID-induced lesions (other than strictures and diaphragms) should improve or completely resolve upon withdrawal of the drug. Endoscopic findings of cobblestoning, longitudinal ulcers, or inflammatory polyps, and histologic findings of granulomas, crypt abscesses, or crypt distortion should suggest Crohn disease instead of NSAIDs. Similarly, the presence of vasculitis on biopsy would favor a collagen vascular disorder. As mentioned above, the diaphragm-like strictures are characteristic for NSAID injury.</p><p class="headingAnchor" id="H9"><span class="h2">Assessment of intestinal permeability</span><span class="headingEndMark"> — </span>Intestinal permeability can be assessed experimentally by measurement of urinary recovery of orally administered test probes such as 51Cr-EDTA [<a href="#rid21">21</a>]. Similarly, localization and quantification of intestinal inflammation can be assessed by 111-Indium-labeled leukocyte scintigraphy and 111-Indium fecal excretion, respectively [<a href="#rid12">12</a>]. Although these radionuclide tests have shed some light on the pathogenesis of NSAID-induced injury, they are of limited clinical use due to lack of availability and their expense.</p><p class="headingAnchor" id="H10"><span class="h1">MANAGEMENT</span><span class="headingEndMark"> — </span>The mainstay of treatment for nonsteroidal antiinflammatory drug (NSAID)-induced injury is discontinuation of the NSAID [<a href="#rid30">30</a>]. For nonstrictured ileocecal lesions, this is usually followed by prompt improvement. If performed, a repeat colonoscopy six to eight weeks later should confirm partial or complete resolution of ulcerations and/or colitis. However, a follow-up colonoscopy is not necessary in the setting of a history and biopsy findings supportive of the diagnosis, as well as symptom resolution. Persistence or worsening of symptoms should raise suspicion for Crohn disease or other causes and investigated accordingly.</p><p>Obstructive symptoms due to strictures are unlikely to resolve without some form of intervention. Endoscopically accessible strictures or diaphragms may be amenable to through-the-scope balloon dilatation  (<a class="graphic graphic_picture graphicRef50670" href="/z/d/graphic/50670.html" rel="external">picture 5</a>) [<a href="#rid31">31</a>] or needle-knife electroincision  (<a class="graphic graphic_picture graphicRef90264" href="/z/d/graphic/90264.html" rel="external">picture 6</a>). However, the diaphragm-like strictures tend to be multiple, often requiring resection of the involved intestinal segment, and, less commonly, strictureplasty [<a href="#rid32">32</a>]. At laparotomy, the absence of serosal abnormalities or palpable areas of transition pinpointing to the enteropathy may be problematic. In such cases, an intraoperative enteroscope placed perorally or through a surgical enterostomy can be used to accurately localize and evaluate the extent of disease, and to better define the intestinal margins for resection [<a href="#rid33">33,34</a>]. Surgery is also indicated for other NSAID-induced complications such as significant bleeding or perforation, and when carcinoma cannot be reliably excluded [<a href="#rid7">7</a>].</p><p class="headingAnchor" id="H2634900"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span>Nonsteroidal antiinflammatory drug (NSAID)-related intestinal injury is common. However, the proportion of patients who develop clinically important NSAID-induced enteropathy is relatively small. (See <a class="local">'Studies of NSAID injury'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>COX-2 inhibitors are not fully protective against clinically important lower gastrointestinal events and may not be more protective than some nonselective NSAIDs. (See <a class="local">'COX-2 inhibitors'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Studies are needed to determine if <a class="drug drug_general" data-topicid="9657" href="/z/d/drug information/9657.html" rel="external">misoprostol</a> decreases the risk of small bowel lesions from NSAIDs. (See <a class="local">'COX-2 inhibitors'</a> above and <a class="local">'Misoprostol'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Most NSAID-induced injuries are subclinical. When present, symptoms and signs of NSAID injury are nonspecific and may include iron deficiency anemia and/or frank bleeding from ulcers; anemia, hypoalbuminemia, or malabsorption from enteropathy; intermittent or complete bowel obstruction from broad-based or diaphragm-like strictures; watery or bloody diarrhea from colitis; and acute abdomen from perforation. (See <a class="local">'Clinical manifestations and diagnosis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Intestinal diaphragms are pathognomonic of NSAID injury. In contrast, erosions, ulcers, or colitis may be due to NSAIDs or another etiology. However, these lesions should improve or completely resolve upon withdrawal of the drug. (See <a class="local">'Intestinal diaphragms'</a> above and <a class="local">'Endoscopic and histologic findings'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The mainstay of treatment for NSAID-induced injury is discontinuation of the NSAID. </p><p></p><p class="bulletIndent1">For nonstrictured ileocecal lesions, discontinuation of the NSAID is usually followed by prompt improvement. If performed, a repeat colonoscopy six to eight weeks later should confirm partial or complete resolution of ulcerations and/or colitis. However, a follow-up colonoscopy is not necessary in the setting of a history and biopsy findings supportive of the diagnosis, as well as symptom resolution. Persistence or worsening of symptoms should raise suspicion for Crohn disease or other causes and investigated accordingly.</p><p></p><p class="bulletIndent1">For strictures or diaphragms causing obstructive symptoms, through-the-scope balloon dilatation or needle-knife electroincision should be performed if they are endoscopically accessible. However, diaphragm-like strictures tend to be multiple, and resection and/or strictureplasty of the involved intestinal segment may be required. </p><p></p><p class="bulletIndent1">Surgery is indicated for other NSAID-induced complications such as significant bleeding or perforation, and when carcinoma cannot be reliably excluded. (See <a class="local">'Management'</a> above.)</p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Goldstein JL, Eisen GM, Lewis B, et al. Video capsule endoscopy to prospectively assess small bowel injury with celecoxib, naproxen plus omeprazole, and placebo. Clin Gastroenterol Hepatol 2005; 3:133.</a></li><li><a class="nounderline abstract_t">Graham DY, Opekun AR, Willingham FF, Qureshi WA. Visible small-intestinal mucosal injury in chronic NSAID users. Clin Gastroenterol Hepatol 2005; 3:55.</a></li><li><a class="nounderline abstract_t">Maiden L, Thjodleifsson B, Theodors A, et al. A quantitative analysis of NSAID-induced small bowel pathology by capsule enteroscopy. Gastroenterology 2005; 128:1172.</a></li><li><a class="nounderline abstract_t">Maiden L, Thjodleifsson B, Seigal A, et al. Long-term effects of nonsteroidal anti-inflammatory drugs and cyclooxygenase-2 selective agents on the small bowel: a cross-sectional capsule enteroscopy study. Clin Gastroenterol Hepatol 2007; 5:1040.</a></li><li><a class="nounderline abstract_t">Sohail R, Mathew M, Patel KK, et al. Effects of Non-steroidal Anti-inflammatory Drugs (NSAIDs) and Gastroprotective NSAIDs on the Gastrointestinal Tract: A Narrative Review. Cureus 2023; 15:e37080.</a></li><li><a class="nounderline abstract_t">Kwo PY, Tremaine WJ. Nonsteroidal anti-inflammatory drug-induced enteropathy: case discussion and review of the literature. Mayo Clin Proc 1995; 70:55.</a></li><li><a class="nounderline abstract_t">Kaufman HL, Fischer AH, Carroll M, Becker JM. Colonic ulceration associated with nonsteroidal anti-inflammatory drugs. Report of three cases. Dis Colon Rectum 1996; 39:705.</a></li><li><a class="nounderline abstract_t">Lang J, Price AB, Levi AJ, et al. Diaphragm disease: pathology of disease of the small intestine induced by non-steroidal anti-inflammatory drugs. J Clin Pathol 1988; 41:516.</a></li><li><a class="nounderline abstract_t">Huber T, Ruchti C, Halter F. Nonsteroidal antiinflammatory drug-induced colonic strictures: a case report. Gastroenterology 1991; 100:1119.</a></li><li><a class="nounderline abstract_t">Kaufmann HJ, Taubin HL. Nonsteroidal anti-inflammatory drugs activate quiescent inflammatory bowel disease. Ann Intern Med 1987; 107:513.</a></li><li><a class="nounderline abstract_t">Gibson GR, Whitacre EB, Ricotti CA. Colitis induced by nonsteroidal anti-inflammatory drugs. Report of four cases and review of the literature. Arch Intern Med 1992; 152:625.</a></li><li><a class="nounderline abstract_t">Bjarnason I, Hayllar J, MacPherson AJ, Russell AS. Side effects of nonsteroidal anti-inflammatory drugs on the small and large intestine in humans. Gastroenterology 1993; 104:1832.</a></li><li><a class="nounderline abstract_t">Langman MJ, Morgan L, Worrall A. Use of anti-inflammatory drugs by patients admitted with small or large bowel perforations and haemorrhage. Br Med J (Clin Res Ed) 1985; 290:347.</a></li><li><a class="nounderline abstract_t">Allison MC, Howatson AG, Torrance CJ, et al. Gastrointestinal damage associated with the use of nonsteroidal antiinflammatory drugs. N Engl J Med 1992; 327:749.</a></li><li><a class="nounderline abstract_t">Matsumoto T, Kudo T, Esaki M, et al. Prevalence of non-steroidal anti-inflammatory drug-induced enteropathy determined by double-balloon endoscopy: a Japanese multicenter study. Scand J Gastroenterol 2008; 43:490.</a></li><li><a class="nounderline abstract_t">Hawkey CJ, Ell C, Simon B, et al. Less small-bowel injury with lumiracoxib compared with naproxen plus omeprazole. Clin Gastroenterol Hepatol 2008; 6:536.</a></li><li><a class="nounderline abstract_t">Smecuol E, Pinto Sanchez MI, Suarez A, et al. Low-dose aspirin affects the small bowel mucosa: results of a pilot study with a multidimensional assessment. Clin Gastroenterol Hepatol 2009; 7:524.</a></li><li><a class="nounderline abstract_t">Laine L, Curtis SP, Langman M, et al. Lower gastrointestinal events in a double-blind trial of the cyclo-oxygenase-2 selective inhibitor etoricoxib and the traditional nonsteroidal anti-inflammatory drug diclofenac. Gastroenterology 2008; 135:1517.</a></li><li><a class="nounderline abstract_t">Laine L, Connors LG, Reicin A, et al. Serious lower gastrointestinal clinical events with nonselective NSAID or coxib use. Gastroenterology 2003; 124:288.</a></li><li><a class="nounderline abstract_t">Watanabe T, Sugimori S, Kameda N, et al. Small bowel injury by low-dose enteric-coated aspirin and treatment with misoprostol: a pilot study. Clin Gastroenterol Hepatol 2008; 6:1279.</a></li><li><a class="nounderline abstract_t">Bjarnason I, Fehilly B, Smethurst P, et al. Importance of local versus systemic effects of non-steroidal anti-inflammatory drugs in increasing small intestinal permeability in man. Gut 1991; 32:275.</a></li><li><a class="nounderline abstract_t">Reuter BK, Davies NM, Wallace JL. Nonsteroidal anti-inflammatory drug enteropathy in rats: role of permeability, bacteria, and enterohepatic circulation. Gastroenterology 1997; 112:109.</a></li><li><a class="nounderline abstract_t">Day TK. Intestinal perforation associated with osmotic slow release indomethacin capsules. Br Med J (Clin Res Ed) 1983; 287:1671.</a></li><li><a class="nounderline abstract_t">Wallace JL, Syer S, Denou E, et al. Proton pump inhibitors exacerbate NSAID-induced small intestinal injury by inducing dysbiosis. Gastroenterology 2011; 141:1314.</a></li><li><a class="nounderline abstract_t">Otani K, Tanigawa T, Watanabe T, et al. Microbiota Plays a Key Role in Non-Steroidal Anti-Inflammatory Drug-Induced Small Intestinal Damage. Digestion 2017; 95:22.</a></li><li><a class="nounderline abstract_t">Scarpignato C, Dolak W, Lanas A, et al. Rifaximin Reduces the Number and Severity of Intestinal Lesions Associated With Use of Nonsteroidal Anti-Inflammatory Drugs in Humans. Gastroenterology 2017; 152:980.</a></li><li><a class="nounderline abstract_t">Matsuhashi N, Yamada A, Hiraishi M, et al. Multiple strictures of the small intestine after long-term nonsteroidal anti-inflammatory drug therapy. Am J Gastroenterol 1992; 87:1183.</a></li><li><a class="nounderline abstract_t">Hayashi Y, Yamamoto H, Kita H, et al. Non-steroidal anti-inflammatory drug-induced small bowel injuries identified by double-balloon endoscopy. World J Gastroenterol 2005; 11:4861.</a></li><li><a class="nounderline abstract_t">Lengeling RW, Mitros FA, Brennan JA, Schulze KS. Ulcerative ileitis encountered at ileo-colonoscopy: likely role of nonsteroidal agents. Clin Gastroenterol Hepatol 2003; 1:160.</a></li><li><a class="nounderline abstract_t">Bielsa-Fernández MV, Tamayo-de la Cuesta JL, Lizárraga-López J, et al. The Mexican consensus on the diagnosis, treatment, and prevention of NSAID-induced gastropathy and enteropathy. Rev Gastroenterol Mex (Engl Ed) 2020; 85:190.</a></li><li><a class="nounderline abstract_t">Hershfield NB. Endoscopic demonstration of non-steroidal anti-inflammatory drug-induced small intestinal strictures. Gastrointest Endosc 1992; 38:388.</a></li><li><a class="nounderline abstract_t">Slesser AA, Wharton R, Smith GV, Buchanan GN. Systematic review of small bowel diaphragm disease requiring surgery. Colorectal Dis 2012; 14:804.</a></li><li><a class="nounderline abstract_t">Abrahamian GA, Polhamus CD, Muskat P, Karulf RE. Diaphragm-like strictures of the ileum associated with NSAID use: a rare complication. South Med J 1998; 91:395.</a></li><li><a class="nounderline abstract_t">Achanta KK, Petros JG, Cave DR, Zinny M. Use of intraoperative enteroscopy to diagnose nonsteroidal anti-inflammatory drug injury to the small intestine. Gastrointest Endosc 1999; 49:544.</a></li></ol></div><div id="topicVersionRevision">Topic 2570 Version 14.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15704047" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Video capsule endoscopy to prospectively assess small bowel injury with celecoxib, naproxen plus omeprazole, and placebo.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15645405" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Visible small-intestinal mucosal injury in chronic NSAID users.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15887101" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : A quantitative analysis of NSAID-induced small bowel pathology by capsule enteroscopy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17625980" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Long-term effects of nonsteroidal anti-inflammatory drugs and cyclooxygenase-2 selective agents on the small bowel: a cross-sectional capsule enteroscopy study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37153279" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Effects of Non-steroidal Anti-inflammatory Drugs (NSAIDs) and Gastroprotective NSAIDs on the Gastrointestinal Tract: A Narrative Review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7808053" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Nonsteroidal anti-inflammatory drug-induced enteropathy: case discussion and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8646963" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Colonic ulceration associated with nonsteroidal anti-inflammatory drugs. Report of three cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3384981" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Diaphragm disease: pathology of disease of the small intestine induced by non-steroidal anti-inflammatory drugs.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2001811" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Nonsteroidal antiinflammatory drug-induced colonic strictures: a case report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3498419" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Nonsteroidal anti-inflammatory drugs activate quiescent inflammatory bowel disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1546927" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Colitis induced by nonsteroidal anti-inflammatory drugs. Report of four cases and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8500743" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Side effects of nonsteroidal anti-inflammatory drugs on the small and large intestine in humans.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3917814" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Use of anti-inflammatory drugs by patients admitted with small or large bowel perforations and haemorrhage.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1501650" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Gastrointestinal damage associated with the use of nonsteroidal antiinflammatory drugs.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18365915" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Prevalence of non-steroidal anti-inflammatory drug-induced enteropathy determined by double-balloon endoscopy: a Japanese multicenter study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18242145" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Less small-bowel injury with lumiracoxib compared with naproxen plus omeprazole.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19249402" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Low-dose aspirin affects the small bowel mucosa: results of a pilot study with a multidimensional assessment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18823986" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Lower gastrointestinal events in a double-blind trial of the cyclo-oxygenase-2 selective inhibitor etoricoxib and the traditional nonsteroidal anti-inflammatory drug diclofenac.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12557133" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Serious lower gastrointestinal clinical events with nonselective NSAID or coxib use.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18995219" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Small bowel injury by low-dose enteric-coated aspirin and treatment with misoprostol: a pilot study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1901563" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Importance of local versus systemic effects of non-steroidal anti-inflammatory drugs in increasing small intestinal permeability in man.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8978349" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Nonsteroidal anti-inflammatory drug enteropathy in rats: role of permeability, bacteria, and enterohepatic circulation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6416544" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Intestinal perforation associated with osmotic slow release indomethacin capsules.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21745447" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Proton pump inhibitors exacerbate NSAID-induced small intestinal injury by inducing dysbiosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28052268" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Microbiota Plays a Key Role in Non-Steroidal Anti-Inflammatory Drug-Induced Small Intestinal Damage.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28007576" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Rifaximin Reduces the Number and Severity of Intestinal Lesions Associated With Use of Nonsteroidal Anti-Inflammatory Drugs in Humans.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1519577" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Multiple strictures of the small intestine after long-term nonsteroidal anti-inflammatory drug therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16097059" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Non-steroidal anti-inflammatory drug-induced small bowel injuries identified by double-balloon endoscopy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15017486" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Ulcerative ileitis encountered at ileo-colonoscopy: likely role of nonsteroidal agents.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32094057" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : The Mexican consensus on the diagnosis, treatment, and prevention of NSAID-induced gastropathy and enteropathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1607099" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Endoscopic demonstration of non-steroidal anti-inflammatory drug-induced small intestinal strictures.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21812898" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Systematic review of small bowel diaphragm disease requiring surgery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9563437" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Diaphragm-like strictures of the ileum associated with NSAID use: a rare complication.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10202079" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Use of intraoperative enteroscopy to diagnose nonsteroidal anti-inflammatory drug injury to the small intestine.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
